<p><strong>Objectives:</strong> Bone is one of the most common organ for metastasis. Bone scintigraphy is widely used for staging of cancer patients before initiation of chemotherapy and adjuvant therapy and it can detect both symptomatic and asymptomatic bone metastases. The purpose of this study was to determine the frequency and site of metastatic bone lesion detected by bone scintigraphy in newly diagnosed asymptomatic cancer patients who werwe referred to National Institute of Nuclear Medicine &amp; Allied Sciences (NINMAS) for bone scintigraphy.</p><p><strong>Patients and Methods:</strong> This cross sectional observational type of study was carried out in NINMAS from July 2015 to June 2016. A total of 116 newly diagnosed asymptomatic cancer patients referred for the first time bone scintigraphy were included in this study.</p><p><strong>Results:</strong> Of the total 116 patients (57 male and 59 female; mean age: 54.8 ± 14.0 years), 46 (39.7%) patients had carcinoma breast, 30 (25.9%) patients had carcinoma prostate, 12(10.3%) patients had carcinoma lung, 8(6.9%) patients had carcinoma urinary bladder, 4(3.4%) patients had renal cell carcinoma and 16(13.8%) patients had other cancer. Bone scan was found positive for metastatic disease in 44.8% patients. Most common sites of bone metastases in different types of cancer in newly diagnosed asymptomatic cancer patients were rib, then hip bone, vertebral column (lumbar vertebra, thoracic vertebra respectively), sternum and skull.</p><p><strong>Conclusion:</strong> In this study, it was revealed that newly diagnosed asymptomatic cancer patients are frequently associated with metastatic bone disease, those can be detected by bone scintigraphy.</p><p>Bangladesh J. Nuclear Med. 20(1): 14-18, January 2017</p>

<p>Skeletal scintigraphy is a highly sensitive tool in the detection of metastatic disease from prostate cancer, but its specificity is relatively low. Various quantitative parameters have been introduced to improve the bone scan specificity. Scintimetric method based Dr. V. Siva’s retention ratio is one such parameter proposed to help in predicting malignant or metastatic nature of the skeletal hot spots in a bone scan non-invasively. This study was performed to evaluate the V. Siva’s ratio in a small sample of prostate cancer patients in Bangladeshi population. This prospective observational study was carried out at the National Institute of Nuclear Medicine and Allied Sciences (NINMAS) from July 2015 to June 2016. A total of 32 patients with diagnosed prostate cancer were enrolled. Each patient underwent two bone scans at 4 hours and 24 hours respectively after radiopharmaceutical injection. Focal hot spots reported by expert Nuclear Medicine specialists were identified in both scans and maximum counts were taken by drawing region of interest over the spots. Dr. V. Siva’s retention ratio was calculated by dividing the 4-hour count with 24-hour count. Finally statistical analysis was done. The mean V. Siva's ratio of metastatic group was 9.3 ± 2.2 (95% CI 8.5-10.1) and that of degenerative group was 8.2 ± 2.0 (95% CI 7.5-8.9). Statistically significant difference was observed between the two groups. So it can be said that V. Siva’s retention ratio might be useful as a quantitative parameter in adjunct to conventional bone scintigraphy for the skeletal survey of carcinoma prostate patients.</p><p>Bangladesh J. Nuclear Med. 20(1): 9-13, January 2017</p>

Objectives: Glomerular filtration rate (GFR) is generally considered to be the best index of renal function in both healthy and diseased kidneys. Calculation of GFR plays a vital

Contrast PET/CT may show layering within the UB, and several examples of have been reported in the literature. But without using contrast this is rare. Our case demonstrates the interesting posterior layering of F18-FDG in urinary bladder in a 78 years old male without the use of contrast. Pulse Volume 12-14 2020-2022 p.32-33

Background: The sentinel lymph node (SLN) is the first draining node from a cancer-bearing area and therefore can manifest metastasis. In breast cancer SLN has been shown to predict the axillary nodal stage. Axillary dissection provides information determining prognosis and need for adjuvant therapy but often carries certain morbidities. Our aim was to determine the feasibility of detecting the SLN and whether the SLN accurately predicts the axillary status. Materials and Methods: Twelve patients having mean age of 40.5 ± 10.9 years, ranging from 28 to 56 years with stage I and II breast cancer and non-palpable axillary nodes from November 2016 to December 2018 were included in this study. The sentinel node was detected with Tc-99m-labelled nano colloid (radiotracer). Dual Head SPECT Gamma Camera and Gamma Probe was used in the same sitting for identification and surface marking of the SLN. Surgical resection of SLN was done followed by frozen section biopsy. Results: The tumor size ranged from <2cm to ≤5cm), SLNs were identified in 11 out of 12 cases, one SLN in 9 patients and two SLNs in remaining two patients during SLN mapping. Conclusion: This was an initial experience in a single hospital, where SLN mapping and biopsy proved feasible and successful. By this method, patients who are negative on frozen section biopsy would be spared from axillary lymph node dissection. However, further practice is required to reach a firm conclusion and long term follow up is also essential. Bangladesh J. Nuclear Med. 24(1&2): 13-17, 2021